AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33988071 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-HCT
Number of subjects: 277
Study 33988071 — intervention group
Group type: COMPARATOR
Intervention: Allo-HCT
Number of subjects: 277
Study 33988071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 277
Study 33028675 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (once-daily oral dosing)
Number of subjects: 2387
Study 34773803 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (900 mg per day)
Number of subjects: 65
Study 34773803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34773803 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 65
Study 34773803 — intervention group
Group type: COMPARATOR
Intervention: Berberine and Placebo
Number of subjects: 65
Study 32599716 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.0055 g·kg−1 post training set)
Number of subjects: 22
Study 32599716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0055 g·kg−1 post training set)
Number of subjects: 22
Study 32599716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Creatine and Placebo)
Number of subjects: 22
Study 35157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg orally twice daily for 24 weeks
Number of subjects: 26
Study 35157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 26
Study 34235415 — intervention group
Group type: EXPERIMENTAL
Intervention: ALRV5XR
Number of subjects: 46
Study 34235415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 32972289 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral clarithromycin twice a day
Number of subjects: 20
Study 32972289 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/kg/day systematic glucantime
Number of subjects: 20
Study 33081762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 236
Study 33081762 — intervention group
Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 236
Study 35267027 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 481
Study 35267027 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 481
Study 35267027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 32691120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg orally
Number of subjects: 200
Study 32691120 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg orally
Number of subjects: 200
Study 34326131 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-1 (IL12 plasmid) administered in eight weekly intraperitoneal infusions starting at cycle 1 week 2 in combination with three 21-day cycles of NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Number of subjects: 18
Study 34326131 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-1 (IL12 plasmid)
Number of subjects: 18
Study 34326131 — intervention group
Group type: COMPARATOR
Intervention: NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Number of subjects: 18
Study 35257062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran (lumasiran/lumasiran group)
Number of subjects: 37
Study 35257062 — intervention group
Group type: COMPARATOR
Intervention: Lumasiran (placebo/lumasiran group)
Number of subjects: 37
Study 35257062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran (both groups)
Number of subjects: 37
Study 35257062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 37
Study 34939363 — intervention group
Group type: EXPERIMENTAL
Intervention: Jujube syrup (10 cc per day)
Number of subjects: 17
Study 34939363 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (10 cc per day)
Number of subjects: 17
Study 32597615 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 48
Study 32597615 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study 35451020 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose (0.5 mL orally)
Number of subjects: 64
Study 35451020 — intervention group
Group type: COMPARATOR
Intervention: 24% sucrose (0.5 mL orally)
Number of subjects: 64
Study 33667495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nocturnal oxygen supplementation (NOS) at 2 L/min
Number of subjects: 40
Study 33667495 — intervention group
Group type: COMPARATOR
Intervention: Sham oxygen (ambient air)
Number of subjects: 40
Study 32044621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 32044621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg
Number of subjects: 217
Study 32044621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg plus Hyoscine‐N‐Butylbromide 10 mg
Number of subjects: 217
Study 35293520 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (300 mg)
Number of subjects: 33
Study 35293520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32186246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicap (capsule containing aspirin, atenolol, ramipril, and simvastatin)
Number of subjects: 100
Study 32186246 — intervention group
Group type: COMPARATOR
Intervention: Control (separate pills for each drug)
Number of subjects: 100
Study 32186246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicap
Number of subjects: 100
Study 33181323 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression during defibrillation
Number of subjects: 100
Study 33181323 — intervention group
Group type: COMPARATOR
Intervention: Standard anterior-posterior defibrillation
Number of subjects: 100
Study 32200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a happy face
Number of subjects: 30
Study 32200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of hand M1 after presentation of a sad face
Number of subjects: 30
Study 32200403 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a neutral face
Number of subjects: 30
Study 32200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of face M1 after presentation of a sad face
Number of subjects: 30
Study 36377106 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 190
Study 36377106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 33251914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-initiated oral anticoagulation (OAC) prescribed within 30 days after surgery to 1,770 patients (24.0% of those with POAF)
Number of subjects: 24523
Study 33251914 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POAF
Number of subjects: 24523
Study 33251914 — intervention group
Group type: COMPARATOR
Intervention: Patients without POAF
Number of subjects: 24523
Study 32788487 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 14
Study 32788487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 14
Study 35436914 — intervention group
Group type: EXPERIMENTAL
Intervention: aerobic physical activity and muscle strengthening exercise
Number of subjects: 196
Study 35436914 — intervention group
Group type: COMPARATOR
Intervention: muscle strengthening exercise only
Number of subjects: 196
Study 33640067 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus Eave Tubes (10% wettable powder formulation of β‐cyfluthrin)
Number of subjects: 2560
Study 33640067 — intervention group
Group type: COMPARATOR
Intervention: Control group (insecticide-treated nets only)
Number of subjects: 2560
Study 33640067 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus Eave Tubes
Number of subjects: 2560
Study 32389076 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-activated braking knee
Number of subjects: 10
Study 36038881 — intervention group
Group type: COMPARATOR
Intervention: Daily Caloric Restriction (DCR)
Number of subjects: 0
Study 36038881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IMF)
Number of subjects: 0
Study 34515902 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous achievement of ACR50 and PASI100 response
Number of subjects: 566
Study 34515902 — intervention group
Group type: COMPARATOR
Intervention: ACR50 response only
Number of subjects: 566
Study 34515902 — intervention group
Group type: COMPARATOR
Intervention: PASI100 response only
Number of subjects: 566
Study 34515902 — intervention group
Group type: COMPARATOR
Intervention: Did not achieve ACR50 or PASI100 response
Number of subjects: 566
Study 35404015 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8895a at 1 mg/kg (Cohort 1)
Number of subjects: 9
Study 35404015 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8895a at 3 mg/kg (Cohort 2)
Number of subjects: 9
Study 35404015 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Zr-DS-8895a
Number of subjects: 9
Study 35404015 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8895a
Number of subjects: 9
Study 33249810 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma separation
Number of subjects: 60
Study 33249810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no platelet separation)
Number of subjects: 60
Study 36364963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy (protein 1.2−1.5 g/kg) and probiotics for two months
Number of subjects: 200
Study 36364963 — intervention group
Group type: COMPARATOR
Intervention: Control group without diet therapy and probiotics
Number of subjects: 200
Study 33076888 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid trigger point injection (TPI)
Number of subjects: 54
Study 33076888 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 54
Study 36154808 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Dorsal Venous Complex (DVC) ligation
Number of subjects: 261
Study 36154808 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Control)
Number of subjects: 261
Study 33396889 — intervention group
Group type: COMPARATOR
Intervention: NORM-EX
Number of subjects: 57
Study 32965160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal linear accelerations ranging from 0.03 Hz at 0.5 mG to 0.2 Hz at 5 mG
Number of subjects: 0
Study 33185243 — intervention group
Group type: COMPARATOR
Intervention: Retrograde LV access
Number of subjects: 144
Study 33185243 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal LV access
Number of subjects: 144
Study 33185243 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 144
Study 36243174 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking during hand hygiene tasks
Number of subjects: 49
Study 33398587 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural VR training
Number of subjects: 26
Study 33398587 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic VR training
Number of subjects: 26
Study 33398587 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 26
Study 33350787 — intervention group
Group type: EXPERIMENTAL
Intervention: ASF (a Compound of Traditional Chinese Medicine)
Number of subjects: 82
Study 33350787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34351816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE), 45 minutes cycling at 70% of estimated V̇O2max
Number of subjects: 30
Study 34351816 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE), 4 sets of 7RM, leg press and knee extension
Number of subjects: 30
Study 34351816 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 32114479 — intervention group
Group type: EXPERIMENTAL
Intervention: iMove exercise intervention (12-week semi-supervised exercise programme)
Number of subjects: 30
Study 32114479 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information booklet about exercise for people with cancer)
Number of subjects: 30
Study 32075607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by trained schoolteachers
Number of subjects: 0
Study 32075607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by nutrition professionals
Number of subjects: 0
Study 34182873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg daily from 16 to 33 weeks of gestation)
Number of subjects: 119
Study 34182873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 34182873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 119
Study 35358063 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (50 mg/kg)
Number of subjects: 22
Study 35358063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33661018 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS (group psychotherapy approach)
Number of subjects: 118
Study 33661018 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 118
Study 33279786 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing a letter expressing appreciation for friend's body functionality
Number of subjects: 154
Study 33279786 — intervention group
Group type: COMPARATOR
Intervention: Writing a letter expressing appreciation for shared memories
Number of subjects: 154
Study 35996884 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation intervention
Number of subjects: 95
Study 35996884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention
Number of subjects: 95
Study 35996884 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention
Number of subjects: 95
Study 35996884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 95
Study 33218742 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + Bupropion (NB) 50/300 mg
Number of subjects: 22
Study 33218742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33218742 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + Bupropion (NB)
Number of subjects: 22
Study 33218742 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone + Bupropion (NB) and Placebo
Number of subjects: 22
Study 32051189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 12573
Study 32051189 — intervention group
Group type: COMPARATOR
Intervention: Non-dengue controls
Number of subjects: 12573
Study 35556946 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (100 - 160 mg based on body mass)
Number of subjects: 15
Study 35556946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35556946 — intervention group
Group type: COMPARATOR
Intervention: YKL-40 (Placebo: 607 ± 386 vs MitoQ 448 ± 241 pg/min, p = 0.544)
Number of subjects: 15
Study 35556946 — intervention group
Group type: COMPARATOR
Intervention: KIM-1 (Placebo: 79.01 ± 38.14 vs MitoQ 69.72 ± 44.26 pg/min, p = 0.362)
Number of subjects: 15
Study 35556946 — intervention group
Group type: COMPARATOR
Intervention: NGAL (Placebo: 20.8 ± 16.8 vs MitoQ 18.9 ± 21.3 ng/min, p = 0.470)
Number of subjects: 15
Study 32526235 — intervention group
Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 134
Study 32526235 — intervention group
Group type: COMPARATOR
Intervention: Fork-tip needle
Number of subjects: 134
Study 33639922 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (tailored group classes twice a week for 16 weeks)
Number of subjects: 24
Study 33639922 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (set activity goals with a research officer and received eight progress calls)
Number of subjects: 24
Study 33639922 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 24
Study 33639922 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 24
Study 32325490 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd
Number of subjects: 207
Study 32325490 — intervention group
Group type: COMPARATOR
Intervention: RVd
Number of subjects: 207
Study 32098633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, interactive online safety and health intervention (iCAN Plan 4 Safety)
Number of subjects: 462
Study 32098633 — intervention group
Group type: COMPARATOR
Intervention: Static, non‐tailored version of the tool
Number of subjects: 462
Study 34303381 — intervention group
Group type: EXPERIMENTAL
Intervention: Early care therapeutic education and psychological intervention program
Number of subjects: 84
Study 34303381 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 84
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic adjuvanted vaccine
Number of subjects: 490
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: One vaccination dose
Number of subjects: 490
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vaccination doses
Number of subjects: 490
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing antibodies before vaccination
Number of subjects: 490
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo anti-HLA antibodies
Number of subjects: 490
Study 33123119 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft rejection
Number of subjects: 490
Study 35073492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT; counseling and conventional sound generators)
Number of subjects: 151
Study 35073492 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Tinnitus Retraining Therapy (pTRT; counseling and placebo sound generators)
Number of subjects: 151
Study 35073492 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC; patient-centered counseling control)
Number of subjects: 151
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessed by Mini Nutritional Assessment-Short Form (MNA-SF)
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB total score
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed (subtest of SPPB)
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 times sit-to-stand test (subtest of SPPB)
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status (MNA-SF)
Number of subjects: 604
Study 34656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of malnutrition or malnutrition (MNA-SF)
Number of subjects: 604
Study 32131745 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based intervention for depression (12-week program including case management and group activities)
Number of subjects: 451
Study 32131745 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based intervention for depression
Number of subjects: 451
Study 32131745 — intervention group
Group type: COMPARATOR
Intervention: Standard Community Mental Health Service (CMHS) care (active control)
Number of subjects: 451
Study 35459660 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive 1 hour CPD course including sex and gender considerations (n=49)
Number of subjects: 127
Study 35459660 — intervention group
Group type: COMPARATOR
Intervention: Similar CPD course without sex and gender considerations (n=78)
Number of subjects: 127
Study 35459660 — intervention group
Group type: COMPARATOR
Intervention: Adjusted for age, gender and practice settings
Number of subjects: 127
Study 33165311 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality tools assessing attrition, missing data, compliance, and related biases in rehabilitation trials
Number of subjects: 0
Study 33165311 — intervention group
Group type: COMPARATOR
Intervention: Existing reporting guidelines (CONSORT and its extensions)
Number of subjects: 0
Study 35366320 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 3569
Study 35366320 — intervention group
Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 3569
Study 34121308 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 272
Study 34121308 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (Lantus®)
Number of subjects: 272
Study 32643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Baixiao moxibustion at meridian sinew nodal points combined with routine rehabilitation
Number of subjects: 50
Study 32643885 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training of the ipsilateral upper and lower limbs
Number of subjects: 50
Study 35249528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led Telephone Survivorship Clinic (TSC)
Number of subjects: 0
Study 32179562 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice daily for a 12-month period
Number of subjects: 120
Study 32179562 — intervention group
Group type: COMPARATOR
Intervention: Cherry-flavoured placebo drink
Number of subjects: 120
Study 34347225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperangulated McGrath X-blade (MGX)
Number of subjects: 210
Study 34347225 — intervention group
Group type: COMPARATOR
Intervention: Macintosh-type CMAC (CM) videolaryngoscope
Number of subjects: 210
Study 33401523 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP educational program
Number of subjects: 0
Study 33401523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35833258 — intervention group
Group type: EXPERIMENTAL
Intervention: JITAIs alongside 16 sessions of CBT
Number of subjects: 56
Study 35833258 — intervention group
Group type: COMPARATOR
Intervention: No JITAIs alongside 16 sessions of CBT
Number of subjects: 56
Study 34469795 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HP + LED/laser
Number of subjects: 20
Study 34469795 — intervention group
Group type: COMPARATOR
Intervention: 6% HP
Number of subjects: 20
Study 32403118 — intervention group
Group type: EXPERIMENTAL
Intervention: POMA 320 mg/d
Number of subjects: 158